ProCE Banner Activity

Pilot Study of CPX-351 in Transplant-Eligible Patients With Previously Untreated Higher-Risk MDS

Slideset Download
Conference Coverage
CPX-351 was associated with a tolerable safety profile and a high response rate in transplant-eligible patients with previously untreated HR-MDS.

Released: December 17, 2021

Expiration: December 16, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation